AN INTERVENTIONAL PHASE 3, OPEN-LABEL, TWO-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FOSMANOGEPIX IN ADULT PATIENTS WITH INVASIVE MOLD INFECTIONS CAUSED BY ASPERGILLUS SPP., FUSARIUM SPP., LOMENTOSPORA PROLIFICANS, MUCORALES FUNGI, OR OTHER MULTI-DRUG RESISTANT MOLDS

Registry ID

FMGX-CS-302

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BASILEA PHARMACEUTICA INTERNATIONAL LTD

Start date

2025-10-20

Last update

2025-05-01

Conditions

• FUNGAL DISEASE

Related clinical trials

• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SAFETY AND EFFICACY OF EL219 (TURLETRICIN) VERSUS LIPOSOMAL AMPHOTERICIN B OR VORICONAZOLE FOR EARLY ANTIFUNGAL THERAPY OF INVASIVE MOULD INFECTIONS (TREAT-1)
• A PHASE III, ADJUDICATOR-BLINDED, RANDOMISED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT WITH OLOROFIM VERSUS TREATMENT WITH AMBISOME® FOLLOWED BY STANDARD OF CARE (SOC) IN PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES

View on source registry